Celtrix Pharmaceuticals, Inc.

Other

Genzyme Corporation

Wendy O Waegell

James R Dasch

Doran R Pace, Iii

Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.

Monoclonal antibodies to transforming growth factor-beta and methods of use

Monoclonal antibodies to transforming growth factor-.beta. and methods

Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications for treating or reducing the likelihood of developing acute or chronic fibrosis utilizing the TGF-B monoclonal antibody are also disclosed.

Monoclonal antibodies to transforming growth factor-beta and methods of

Monoclonal antibodies have been produced which bind to Transforming Growth Factors .beta.1 (TGF-.beta.1) and .beta.2 (TGF-.beta.2). The monoclonal antibody produced by the hybridoma designated 1D11.16 deposited as A.T.C.C. Accession No. HB 9849 binds to both TGF-.beta.1 and TGF-.beta.2. The antibodies are produced by immunizing with TGF-.beta.2 and may be of any isotype. The antibodies may be of any mammalian origin such as murine or human origin. Diagnostic and therapeutic applications utilizing the monoclonal antibodies are also disclosed.

Growing community of inventors

Mountain View, CA, United States of America

Wendy O Waegell